阿培利司联合氟维司群治疗PIK3CA突变型与野生型雌激素受体阳性晚期乳腺癌:一项1b期临床试验
这项开放标签、单臂1b期研究在5个国家10个中心纳入87例内分泌治疗耐药的ER+晚期乳腺癌绝经后女性,评估阿培利司联合氟维司群的MTD、安全性和活性。联合氟维司群时阿培利司MTD为400 mg每日一次,推荐2期剂量为300 mg每日一次;PIK3CA突变型较野生型PFS更长(9.1个月 vs 4.7个月),野生型无客观缓解。
要点
- 阿培利司联合氟维司群的MTD为400 mg每日一次,推荐2期剂量为300 mg每日一次。
- 400 mg剂量下最常见3/4级不良事件为高血糖(22%)和斑丘疹(13%),9例因不良事件永久停药。
- PIK3CA突变型PFS 9.1个月 vs 野生型4.7个月,突变型ORR 29%,野生型无客观缓解。
核心结论
- 阿培利司联合氟维司群在ER+晚期乳腺癌患者中安全性可控,数据提示该联合方案在PIK3CA突变型肿瘤中可能较野生型具有更大的临床活性。
研究设计与样本
- 开放标签、单臂1b期研究,在5个国家10个中心开展,纳入87例PIK3CA突变型或野生型ER+晚期乳腺癌绝经后女性,抗癌治疗中位既往线数为5线。
- 研究于2010年10月5日开始入组,数据截止2017年3月22日;剂量递增阶段阿培利司起始300 mg每日一次联合固定剂量氟维司群500 mg,扩展阶段采用推荐2期剂量。
- 主要终点为确定阿培利司每日一次联合氟维司群的MTD,次要终点包括安全性和初步活性。
主要发现
- 剂量递增阶段1例患者(阿培利司400 mg)报告剂量限制性毒性:腹泻(2级)、呕吐、疲乏和食欲下降(均为3级)。
- 阿培利司400 mg每日一次联合氟维司群时,最常见的3/4级不良事件(≥10%患者,不论因果关系)为高血糖(19例[22%])和斑丘疹(11例[13%]);9例患者因不良事件永久停药。
- MTD下中位无进展生存期为5.4个月(95%CI,4.6-9.0个月)。
- 阿培利司300至400 mg每日一次联合氟维司群时,PIK3CA突变型肿瘤中位PFS为9.1个月(95%CI,6.6-14.6个月),野生型为4.7个月(95%CI,1.9-5.6个月)。
- PIK3CA突变组客观缓解率为29%(95%CI,17%-43%),野生型组无客观肿瘤缓解。
关键数值与推荐
- 阿培利司联合氟维司群的MTD为400 mg每日一次。
- 阿培利司联合氟维司群的推荐2期剂量为300 mg每日一次。
- 剂量递增阶段阿培利司剂量水平:300 mg(n=9)、350 mg(n=8)、400 mg(n=70),均联合氟维司群500 mg固定剂量。
临床怎么用
- 作者认为阿培利司联合氟维司群在ER+晚期乳腺癌中安全性可控,数据提示该联合方案在PIK3CA突变型较野生型肿瘤中可能具有更大临床活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor-positive (ER+), endocrine therapy-resistant breast cancers. OBJECTIVE: To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibitor, plus fulvestrant in patients with ER+ advanced breast cancer (ABC). DESIGN, SETTING, AND PARTICIPANTS: An open-label, single-arm, phase 1b study of alpelisib plus fulvestrant was conducted at 10 centers in 5 countries. Participants were 87 postmenopausal women with PIK3CA-altered or PIK3CA-wild-type ER+ ABC, whose cancer progressed during or after antiestrogen therapy. The study began enrolling patients October 5, 2010, and the data cutoff was March 22, 2017. INTERVENTIONS: Escalating doses of alpelisib were administered once daily, starting at 300 mg, plus fixed-dose fulvestrant, 500 mg, in the dose-escalation phase; alpelisib at the recommended phase 2 dose plus fulvestrant in the dose-expansion phase. MAIN OUTCOMES AND MEASURES: The primary end point was determination of the MTD of once-daily alpelisib plus fulvestrant. Secondary end points included safety and preliminary activity. RESULTS: From October 5, 2010, to March 22, 2017, 87 women (median age: 58 years [range, 37-79 years]; median of 5 prior lines of antineoplastic therapy) received escalating once-daily doses of alpelisib (300 mg, n = 9; 350 mg, n = 8; 400 mg, n = 70) plus fixed-dose fulvestrant (500 mg). During dose escalation, dose-limiting toxic effects were reported in 1 patient (alpelisib, 400 mg): diarrhea (grade 2), vomiting, fatigue, and decreased appetite (all grade 3). The MTD of alpelisib when combined with fulvestrant was 400 mg once daily, and the recommended phase 2 dose was 300 mg once daily. Overall, the most frequent grade 3/4 adverse events with alpelisib, 400 mg, once daily (≥10% of patients), regardless of causality, were hyperglycemia (19 [22%]) and maculopapular rash (11 [13%]); 9 patients permanently discontinued therapy owing to adverse events. Median progression-free survival at the MTD was 5.4 months (95% CI, 4.6-9.0 months). Median progression-free survival with alpelisib, 300 to 400 mg, once daily plus fulvestrant was longer in patients with PIK3CA-altered tumors (9.1 months; 95% CI, 6.6-14.6 months) vs wild-type tumors (4.7 months; 95% CI, 1.9-5.6 months). Overall response rate in the PIK3CA-altered group was 29% (95% CI, 17%-43%), with no objective tumor responses in the wild-type group. CONCLUSIONS AND RELEVANCE: Alpelisib plus fulvestrant has a manageable safety profile in patients with ER+ ABC, and data suggest that this combination may have greater clinical activity in PIK3CA-altered vs wild-type tumors. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01219699.
引用
- Juric D, Janku F, Rodón J, et al. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2019. PMID: 30543347. doi:10.1001/jamaoncol.2018.4475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。